


Data Sheet

Product Name: Glimepiride
Cat. No.: CS-1844
CAS No.: 93479-97-1
Molecular Formula: C24H34N4O5S

Molecular Weight: 490.62
Target: Others
Pathway: Others

Solubility: DMSO: 33.33 mg/mL (67.93 mM; Need ultrasonic); H2O: < 0.1

mg/mL (insoluble)



BIOLOGICAL ACTIVITY:

Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED₅₀ of 182 μ g/kg. IC50 & Target: DPP4^[1]. **In Vivo**: Glimepiride (Glimperide) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more^[1]. Glimepiride (Glimperide) decreased extracellular A β 40 and A β 42 levels. glimepiride may serve as a promising drug for the treatment of AD associated with diabetes^[2]. Glimepiride (Glimperide) was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride (Glimperide) use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning^[3].

References:

- [1]. Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38(8): p. 1120-30.
- [2]. Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4.
- [3]. Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag, 2012. 8: p. 463-72.

CAIndexNames:

 $1 \\H-Pyrrole-1-carboxamide, \\3-ethyl-2, \\5-dihydro-4-methyl-N-[2-[4-[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-[((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-[((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-[((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]-2-oxo-linear \\4-methyl-N-[2-[4-((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]-2-oxo-linear \\4-methyl-N-[4-[4-((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]-2-oxo-linear \\4-methyl-N-[4-((trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]-2-oxo-linear \\4-methyl-N-[4-((trans-4-methylcyclohexyl)amino]carbonyl]-2-oxo-linear \\4-methyl-N-[4-((trans-4-methylcyclohexyl)amino]carbonyl-1-oxo-linear \\4-methyl-N-[4-((trans-4-methylcyclohexyl)amino]carbonyl-1-oxo-linear \\4-methyl-N-$

SMILES:

O = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3) = O) = O)C = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3) = O) = O)C = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3) = O) = O)C = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3) = O) = O)C = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3) = O) = O)C = C(N1C(C(CC) = C(C)C1) = O)NCCC2 = CC = C(S(C(C)C(C)C1) = O)NCCC2 = CC = C(S(C(C)C)C1) = O)NCCCC2 = CC = C(S(C)C)C1) = O(S(C(C)C)C1) = O(S(C(C)C)C1) = O(S(C)C1) = O(S(

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com